✦ LIBER ✦

570 A new approach in hormonotherapy of advanced breast cancer: Sequential hormonal combination

✍ Scribed by A. Pellegrini; B. Massidda; V. Mascia

Book ID: 116004022
Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 134 KB
Volume: 19
Category: Article
ISSN: 0022-4731
DOI: 10.1016/0022-4731(83)92071-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

539 A new strategy in the treatment of a

539 A new strategy in the treatment of advanced breast cancer: Sequential hormones

✍ S. Iacobelli; C. Natoli; G. Scambia 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 115 KB

586 Survival data of a combination versu

586 Survival data of a combination versus sequential hormonal therapy add cytotoxic chemotherapy in advanced breast cancer

✍ David T. Kianq; B.J. Kennedy 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Results of combined hormone therapy in a

Results of combined hormone therapy in advanced breast cancer

✍ Edward F. Lewison; Frances H. Trimble; John L. Grow; Teruo Masukawa 📂 Article 📅 1963 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB 👁 2 views

Survival data of a combination versus se

Survival data of a combination versus sequential hormonal therapy and cytotoxic chemotherapy in advanced breast cancel

✍ DavidT. Kiang; B.J. Kennedy 📂 Article 📅 1983 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Analysis of some prognostic factors in a

Analysis of some prognostic factors in advanced breast cancer treated with simultaneous or sequential hormonotherapy (HT) and chemotherapy (CT)

📂 Article 📅 1982 🏛 Elsevier Science ⚖ 137 KB

Combination therapy of hormone and cytot

Combination therapy of hormone and cytotoxic agents in advanced breast cancer

✍ David T. Kiang; Daniel H. Frenning; Juliette Gay; Anne I. Goldman; B. J. Kennedy 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 2 views

The effectiveness of combination therapy with diethylstilbestrol, cyclophosphamide, and 5-fluorouracil (DES + CTx + FU) was compared with DES alone or CTx + FU in 87 postmenopausal women with advanced breast cancer. Therapy was randomized according to the tumor estrogen-receptor (ER) status. In 30